Immix Biopharma, Inc. Net Income Loss

Quick Answer

Immix Biopharma, Inc. reported Net Income Loss of -$29.44 million for the year ending 2025.

  • Immix Biopharma, Inc. showed a decrease of -36.2% in Net Income Loss from 2024 to 2025.
  • This data is from Immix Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), Immix Biopharma, Inc.'s Net Income Loss has declined by 2,464.6%.
  • Historical annual values: Fiscal year 2025: -$29.44 million | Fiscal year 2024: -$21.61 million | Fiscal year 2023: -$15.43 million | Fiscal year 2022: -$8.23 million | Fiscal year 2021: -$24.38 million | Fiscal year 2020: -$1.15 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: